


**Bismuth(III)-catalyzed cycloisomerization and
(hetero)arylation of alkynols: a simple access to 2-(hetero)aryl
tetrahydrofurans and tetrahydropyrans**

Ashwini K. Nakate, Madhukar S. Pratapure and Ravindar Kontham


Electronic Supplementary Information

S No	Contents	Page No
1	Synthesis of Alkynols (4-Pentyn-1-ols)	S3
2	Synthesis of Alkynols (5-Hexyn-1-ols)	S7
3	Key NOE interactions in compounds 3aa , 3la , 5ba and 5ca (Figures 1-4)	S10
4	^1H , ^{13}C and 2D NMR Spectra/HPLC Reports	S12


1. Synthesis of Alkynols (4-Pentyn-1-ols):



Compound **1a-j**, **1l** & **1q** were prepared using known literature procedures.¹ **1k** and **1r** was prepared using reported procedure.² **1o** was purchased from commercial sources.



((1-(Prop-2-yn-1-yl) cyclopentyl) methoxy) tetrahydro-2H-pyran (**1a'**):




¹ Kambale, D. A.; Thorat, S. S.; Pratapure, M. S.; Gonnade, R. G.; Kontham, R. *Chem. Commun.*, **2017**, 53, 6641–6644.

² Fananas, F. J.; Fernandez, A.; Cevic, D.; Rodriguez, F. *J. Org. Chem.* **2009**, 74, 932-934.


((1-(Prop-2-yn-1-yl) cyclopentyl) methoxy) tetrahydro-2H-pyran (**1a'**) was prepared using reported procedure¹. ¹H NMR (CDCl₃, 200MHz) δ 4.61 (m, 1H) 3.97-3.79 (m, 1H), 3.62 (d, *J* = 9.35 Hz, 1H), 3.57-3.35 (m, 1H), 3.19 (d, *J* = 9.35 Hz, 1H), 2.31 (t, *J* = 2.40 Hz, 2H), 1.91 (t, *J* = 2.65 Hz, 1H), 1.67-1.56 (m, 14H).

2-((1-(But-2-yn-1-yl) cyclopentyl) methoxy) tetrahydro-2H-pyran (1b'**):**




2-((1-(But-2-yn-1-yl)cyclopentyl) methoxy) tetrahydro-2H-pyran (**1b'**) was prepared using reported procedure¹. ¹H NMR (CDCl₃, 200 MHz) δ 4.66-4.55 (m, 1 H), 3.97-3.79 (m, 1 H), 3.61 (d, *J* = 9.09 Hz, 1 H), 3.56-3.44 (m, 1 H), 3.17 (d, *J* = 9.09 Hz, 1 H), 2.27-2.19 (m, 2H), 1.78 (t, *J* = 2.53 Hz, 3 H), 1.67-1.42 (m, 14 H).

(1-(But-2-yn-1-yl) cyclopentyl) methanol (1b**):**




(1-(But-2-yn-1-yl) cyclopentyl) methanol (**1b**) was prepared using reported procedure¹. ¹H NMR (CDCl₃, 200 MHz) δ 3.50 (s, 2H), 2.18-2.12 (m, 2H), 2.08 (m, 1H), 1.78 (t, *J* = 2.59 Hz, 3H), 1.68-1.53 (m, 4H), 1.53-1.40 (m, 4H).

2-((1-(but-2-yn-1-yl)cyclopentyl)methoxy)tetrahydro-2H-pyran (1d**):**




2-((1-(but-2-yn-1-yl)cyclopentyl)methoxy)tetrahydro-2H-pyran (**1d**) was prepared using reported procedure¹, by using crude (**1d'**). ¹H NMR (CDCl₃, 200 MHz) δ 7.39-7.15 (m, 5 H), 3.61-3.55 (m, 2 H), 3.53-3.50 (m, 2 H), 2.37-2.23 (m, 2 H), 1.95 (d, *J* = 2.65 Hz, 1 H), 1.66-1.57 (m, 4 H), 1.54-1.46 (m, 4 H); ¹³C NMR (CDCl₃, 50 MHz) δ 131.6, 128.2, 127.6, 123.8, 87.6, 82.8, 68.7, 38.2, 32.0, 26.2, 26.1, 21.6, 14.2.

2-(prop-2-yn-1-yl)cyclohexan-1-one (**S0**):



To a flame dried (100 mL) two neck round bottom flask, anhydrous THF (30 mL) was added under argon atmosphere and cooled it to -78 °C, to this diisopropylamine (4.35 mL, 3.05 mmol) followed by *n*-butyllithium (1.6 M in hexanes, 19 mL,) was added drop wise at -78 °C and stirred for 45 min at 0 °C to generate LDA solution. To this LDA solution was added cyclohexanone (**S**) (3.75 mL, 3.05 mmol) in THF (20 mL) and stirred the reaction mixture at -78 °C for 30 min, then warmed to 0 °C and stirred for another 30 min. Reaction mixture was cooled back to -78 °C and propargyl bromide (80% in toluene, 2.31 mL, 3.05 mmol) was added drop wise. The resulting mixture was stirred at -78 °C for 1 h and warmed to 25 °C and stirred for overnight. The reaction was quenched with saturated aqueous NH₄Cl solution and extracted with EtOAc (3x25 mL), combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to afford 2-(prop-2-yn-1-yl)cyclohexan-1-one (**S0**) crude which was subjected to the next step without further purification. (1.5 g) TLC: *R_f* = 0.6.

2-(Prop-2-yn-1-yl)cyclohexan-1-ol(**1n**) & 2-(prop-2-yn-1-yl)cyclohexan-1-ol (**1m**);




To a solution of 2-(prop-2-yn-1-yl)cyclohexan-1-one (**S0**) (1.5 g 11.01 mmol) in methanol (10 mL), sodium borohydride (0.25 g, 6.61 mmol) was slowly added at 0 °C. The reaction mixture was stirred at 0 °C for 30 min and then for 2.5 h at room temperature, after which the solvent was evaporated under reduced pressure. Aqueous NH₄Cl solution (10 mL) was added to the resulting suspension, and then extracted with EtOAc (3×5 mL). Organic phases were combined and dried over anhydrous Na₂SO₄, filtered and the solvent was evaporated under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (SiO₂, 2% EtOAc/hexanes) to afford a mixture of alcohols **1n** (1,2-*cis*) (614 mg, 50%, colourless liquid) and **1m**, (1,2-*trans* fused) (694 mg, 57%, colourless liquid). TLC: *R_f* = 0.4 & 0.1 (SiO₂, 2% EtOAc/hexanes);

Data for **1n**: ¹H NMR (CDCl₃, 500 MHz) (*cis*): δ 4.07 (s, 1H), 2.31 (ddd, *J* = 16.78, 7.82, 2.67 Hz, 1H), 2.18 (ddd, *J* = 16.78, 6.87, 2.67 Hz, 1H), 2.0 (t, *J* = 2.67 Hz, 1H), 1.86-1.77 (m, 1H), 1.71-1.59 (m, 3H), 1.59-1.40 (m, 5H), 1.34-1.23 (m, 1H); ¹³C NMR (CDCl₃, 126 MHz): δ 83.5, 69.2, 68.3, 40.8, 32.9, 26.2, 25.1, 21.5, 20.1.

Data for **1m**: ¹H NMR (CDCl₃, 500 MHz) δ 3.39-3.37 (m, 1H), 2.49-2.43 (m, 1H), 2.32 (ddd, *J* = 16.78, 6.87, 2.67 Hz, 1H), 2.02-1.95 (m, 3H), 1.84-1.89 (m, 1H), 1.79-1.73 (m, 1H), 1.71-1.65 (m, 2H), 1.49-1.40 (m, 1H), 1.31-1.15 (m, 4H),); ¹³C NMR (CDCl₃, 126 MHz): δ 82.9, 73.5, 69.7, 43.9, 35.5, 30.2, 25.4, 24.8, 21.7.


2-(1-(prop-2-yn-1-yl)cyclohexyl)propan-2-ol (**1h**)



To a flame dried (100 mL) two neck round bottom flask, methyl 1-(prop-2-yn-1-yl)cyclohexane-1-carboxylate (**1h'**) (2 g, 1.10 mmol) in anhydrous THF (30 mL) and cooled it to 0 °C followed by methyl magnesium bromide (1.0 M THF) (22 mL, 2.77 mmol) was added drop wise under argon atmosphere after completion of addition gradually increased temperature to rt. Reaction monitored by TLC, after completion of reaction quenched with Aqueous NH₄Cl solution (10 mL), extracted with EtOAc (3×5 mL). Organic phases were


combined and dried over anhydrous Na_2SO_4 , filtered and the solvent was evaporated under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (SiO_2 , 4% EtOAc/hexanes) to afford a mixture of alcohols **1h** (2-(1-(prop-2-yn-1-yl)cyclohexyl)propan-2-ol) (1.43 g, 71%) as a colourless liquid. ^1H NMR (CDCl_3 , 500 MHz) δ 2.43 (d, $J = 2.78$, 2H), 2.33 (br. s, 1H), 2.8 (t, $J = 2.78$, 1H), 1.71-1.32 (m, 10H), 1.25 (s, 6H).

Synthesis of Alkynols (5-Hexyn-1-ols):




Alkynol **4a** was purchased from commercial sources.

Hept-6-yn-2-ol (4b):



Hept-6-yn-2-ol (**4b**) was prepared using reported procedure.³ ^1H NMR (CDCl_3 , 500 MHz): δ 3.87-3.78 (m, 1H), 2.24-2.19 (m, 2H), 1.97 (t, $J = 2.6$ Hz, 1H), 1.70-1.50 (m, 4H), 1.20 (d, $J = 6.1$ Hz, 3H); ^{13}C NMR (CDCl_3 , 126 MHz): δ 84.3, 68.5, 67.6, 38.2, 24.7, 23.6, 18.4.


5-(But-3-yn-1-yl)-4-hydroxydihydrofuran-2(3H)-one (4c):



³ Shibata, N.; Tsuchiya, T.; Hashimoto, Y.; Morita, N.; Ban, S.; Tamura, O. *Org. Biomol. Chem.*, **2017**, *15*, 3025–3034.


(See below experimental procedures and data)

Methyl-(*E*)-oct-3-en-7-ynoate (S2):



A freshly prepared solution of piperidinium acetate (by mixing piperidine (35 μ L, 0.41 mmol) and acetic acid (20 μ L, 0.37 mmol)) in DMSO (1 mL) was injected in to a stirred solution of the readily available hept-5-ynal (**S1**) (1.5 g, 15.61 mmol) and malonic acid (3.24 g, 31.2 mmol), in DMSO (40 mL), the resulting reaction mixture was stirred for 6 h at 160 $^{\circ}$ C. Then it was quenched by adding water and extracted with diethyl ether (3x50 mL) and dried over anhydrous sodium sulphate, concentrated under reduced pressure to afford crude (*E*)-oct-3-en-7-ynoic acid, which was subjected to the next step without further purification. The (*E*)-oct-3-en-7-ynoic acid (0.9 g, 6.51 mmol) was dissolved in methanol (5 mL), then amberlyst-15 (2.05 g, 6.5 mmol) was added to the reaction mixture and refluxed for 1 h. The reaction mixture was cooled to room temperature and filtered through sintered funnel and washed with diethyl ether (20 mL) and dried over anhydrous sodium sulphate. Then, filtered using sintered funnel and concentrated under reduced pressure. Purification of the crude product by column chromatography (SiO_2 , 2% EtOAc/hexanes) afforded the pure methyl-(*E*)-oct-3-en-7-ynoate (**S2**) (1.6 g, 78%) as a yellow oil. TLC: R_f = 0.8 (SiO_2 , 30% EtOAc/hexanes); ^1H NMR (CDCl_3 , 500 MHz) δ 5.69-5.59 (m, 2H), 3.69 (s, 3H), 3.11-3.03 (m, 2H), 2.34-2.21 (m, 4H), 1.97 (s, 1H); ^{13}C NMR (CDCl_3 , 126 MHz) δ 172.3, 132.3, 123.1, 83.7, 68.7, 51.7, 37.7, 31.4, 18.5.


5-(But-3-yn-1-yl)-4-hydroxydihydrofuran-2(3H)-one (4c):




To a solution of methyl (*E*)-oct-3-en-7-ynoate (**S2**) (0.1g, 0.66mmol) in 2 mL of t-BuOH:H₂O (1:1) in a single neck round bottom flask, was added AD-mix- α (0.92 g, 0.66

mmol) and methane sulfonamide (0.062 g, 0.66) at 0 °C. The resulting reaction mixture was stirred for 36 h at 0 °C under argon atmosphere. Then it was quenched with saturated aqueous solution of sodium sulphite (Na₂SO₃), then extracted with *t*-BuOMe (2x10 mL), dried over anhydrous sodium sulphate. Filtered and concentrated under reduced pressure. The crude mixture was purified by silica gel column chromatography (SiO₂, 40% EtOAc/hexanes) to afford 5-(but-3-yn-1-yl)-4-hydroxydihydrofuran-2(3*H*)-one (**4c**) (0.080 g, 79%) as a colourless oil. TLC: *R_f* = 0.12 (SiO₂, 40% EtOAc/hexanes); ¹H NMR (CDCl₃, 200 MHz) δ 4.66-4.5 (m, 2H), 2.83 (dd, *J* = 17.8, 5.05 Hz, 1H), 2.64-2.5 (m, 1H), 2.49-2.26 (m, 2H), 2.23-1.86 (m, 3H); ¹³C NMR (CDCl₃, 101 MHz) δ 176.1, 83.7, 83.1, 69.6, 68.6, 39.3, 27.1, 14.7.

2-(Prop-2-yn-1-yloxy)ethan-1-ol (4d):




2-(prop-2-yn-1-yloxy)ethan-1-ol (**4d**) was prepared using reported procedure.⁴ ¹H NMR (CDCl₃, 200 MHz): δ 4.23-4.11 (m, 2H), 3.75-3.71 (m, 2H), 3.67-3.57 (m, 2H), 2.64 (br.s, 1H), 2.45 (t, *J* = 2.4 Hz, 1H); ¹³C NMR (CDCl₃, 50 MHz): δ 79.5, 74.8, 71.3, 61.6, 58.4.



2a, 2b, 2c, 2d, 2e and **2f** were purchased from commercial sources.

⁴ Harada, T.; Muramatsu, K.; Mizunashi, K.; Kitano, C.; Imaoka, D.; Fujiwara, T.; Kataoka, H. *J. Org. Chem.*, **2008**, *73*, 249–258.



Compounds **6a** and **6c** are purchased from commercial sources.

Compound **6b** was prepared using known procedure.⁵




Figure 1. Key NOE interactions in compound **3aa**.




Figure 2. Key NOE interactions in compound **3la**.

⁵Jeanese, C. B.; Jason, A. J.; Gordon, W. G.; *Tetrahedron Letters*, **2013**, *54*, 2759–2762.




Figure 3. Key NOE interactions in compound **5ba**.







Figure 4. Key NOE interactions in compound **5ca**.

^1H , ^{13}C and 2D NMR Spectra
/HPLC Reports









1b

^1H NMR, 200 MHz

CDCl_3










1n


^1H NMR, CDCl_3
500 MHz



1n



^{13}C NMR, CDCl_3
126 MHz






1m


^1H NMR, CDCl_3
500 MHz




1m

^{13}C NMR, CDCl_3
126 MHz










4b


^1H NMR, CDCl_3
500 MHz



4b

^{13}C NMR, CDCl_3
126 MHz







S2

^1H NMR, CDCl_3


500 MHz






S2

^{13}C NMR, CDCl_3

126 MHz










4d



^1H NMR, CDCl_3
200 MHz




4d

^{13}C NMR, CDCl_3
50 MHz







(3aa):




HMBC (3aa):







HSQC (3aa):




NOESY (3aa):












3ac¹



¹H NMR, CDCl₃
200 MHz






3ac¹

¹³C NMR, CDCl₃
50 MHz
















3ae
¹H NMR CDCl₃
200 MHz







3ae
¹³C NMR CDCl₃
50 MHz


















































COSY (3la):




HMBC (3la):




HSQC (31a):







Expanded NOESY (31a):







NOESY (3la):

















5ba

^1H NMR, CDCl_3
400MHz




5ba


^{13}C NMR, CDCl_3
101MHz




COSY (5ba):




HMBC (5ba):




HSQC (5ba):




NOESY (5ba):



Expanded NOESY (5ba):







5ca

$^1\text{H NMR}$, CDCl_3


500 MHz




5ca

$^{13}\text{C NMR}$, CDCl_3


126 MHz




COSY (5ca):




HMBC (5ca):




HSQC (5ca):






NOESY (5ca):



NOESY (5ca):









7aa

^1H NMR, CDCl_3


200 MHz




7aa



^{13}C NMR, CDCl_3

50 MHz






7aa¹, (dr, 1:3)
¹H NMR, CDCl₃
200 MHz



7aa¹, (dr, 1:3)
¹³C NMR, CDCl₃
50 MHz



HPLC Analysis Report (7aa¹)

D-7000 HPLC System Manager Report

Analyzed: 11/06/17 04:35 PM

Reported: 11/06/17 05:00 PM

Processed: 11/06/17 04:59 PM

Data Path: C:\WIN32APP\HSM\HPLC\DATA\9916\

Processing Method: cal

System(acquisition): Sys 1

Series:9916

Application: HPLC


Volume: 10.0 ul

Sample Name: AN-03

Injection from this vial: 1 of 1

Sample Description: IPA:PE(01:99)



Chrom Type: HPLC Channel : 1







No.	RT	Area	Conc 1	BC
1	4.08	5338034	82.837	BB
2	6.28	1105998	17.163	BB
		6444032	100.000	


Peak rejection level: 0

Project Leader: Dr.RAVINDAR KONTHAM
Column :Chiralcel OJ-H(250 mm x 4.6mm)
Mobile Ph : IPA:PE(01:99)
Wavelength : 220nm
Flow : 1 ml/min.
Inject vol: 2ul











7ia

$^1\text{H NMR}$, CDCl_3


200 MHz





7ia

$^{13}\text{C NMR}$, CDCl_3

50 MHz





HPLC Analysis Report (7ia¹)

D-7000 HPLC System Manager Report

Analyzed: 11/06/17 02:37 PM

Reported: 11/06/17 03:04 PM

Processed: 11/06/17 03:03 PM

Data Path: C:\WIN32APP\HSM\HPLC\DATA\9910\

Processing Method: cal

System(acquisition): Sys 1

Series:9910

Application: HPLC


Volume: 10.0 ul

Sample Name: AN=04

Injection from this vial: 1 of 1

Sample Description: IPA:PE(02:98)



Chrom Type: HPLC Channel : 1







No.	RT	Area	Conc 1	BC
1	8.47	18643153	49.990	BB
2	14.59	18650707	50.010	BB
		37293860	100.000	


Peak rejection level: 0

Project Leader: Dr.RAVINDAR KONTHAM
Column :Kromasil 5-cellucoat(250 mm x 4.6mm)
Mobile Ph : IPA:PE(02:98)
Wavelength : 220nm
Flow : 1 ml/min.
Inject vol: 5ul











7ab

$^1\text{H NMR}$, CDCl_3
400 MHz



7ab

$^{13}\text{C NMR}$, CDCl_3
101 MHz

